POSSIBILITIES OF RESIDUAL DYSLIPIDEMIA CORRECTION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS, WHO ARE RECEIVING OPTIMAL STATIN THERAPY
- Authors: Bogdanov A.R.1,2,3, Pyko M.E.4, Pyko A.A.5,6
-
Affiliations:
- Pirogov Russian National Research Medical University
- Russian State Social University
- City Clinical Hospital №13, Moscow
- Federal Research Centre of Nutrition and Biotechnology
- Pavlov Ryazan State Medical University
- Medical unit of the Ministry of Internal Affairs of Russia in the Ryazan Region
- Issue: Vol 22, No 1 (2020)
- Pages: 54-60
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/95211
- DOI: https://doi.org/10.26442/20751753.2020.1.200057
- ID: 95211
Cite item
Full Text
Abstract
Background. Patients with multifocal atherosclerosis with maximal cardiovascular risk are at special place in the context of lipid-lowering therapy optimization. These patients require residual dyslipidemia correction to the fullest extent possible. Materials and methods. Effects of medication Vasosponine (ZAO “Vifitekh”, Russia) which is a source of vegetal saponins in a dosage 400 mg per day on serum lipid profile parameters were evaluated in patients with multifocal atherosclerosis and non-target levels of atherogenic lipoproteins while receiving optimal statin treatment. The study included 100 patients with stable coronary artery disease and high cardiovascular risk with an experience of myocardial infarction or percutaneous coronary intervention in the last 2-12 months and diagnosed with obliterating atherosclerosis of peripheral arteries - brachiocephalic arteries and/or lower extremities arteries. Study group (n=50) included patients who received combined lipid-lowering therapy: atorvastatin in dosage 40 mg per day + Vasosponine 400 mg per day along with baseline treatment. Control group included 50 patients receiving only atorvastatin in dosage 40 mg per day along with baseline treatment. Total duration of the study was 6 months: with screening for 30 days and patient follow-up for 90 days. The study included 3 endpoints at 1 st, 10th, and 90th days of treatment. Results. It was shown that adding of Vasosponine to treatment allows results in significant and stable decrease of total cholesterol level by 30.7% (p<0.001), low-density lipoprotein level by 37.2% (p<0.001), triglycerides level by 37.0% (p<0.0001), and atherogenic index by 39.5% after 90 days of treatment. Vasosponine was established to have good safety profile. Conclusion. Medications containing vegetal saponins may be used in escalation schemes of lipid-lowering therapy in patients who did not achieve target levels of lipids after treatment with optimal statin doses.
Full Text
##article.viewOnOriginalSite##About the authors
Alfred R. Bogdanov
Pirogov Russian National Research Medical University; Russian State Social University; City Clinical Hospital №13, Moscow
Email: bogdanov.ar@mail.ru
д-р мед. наук, проф. каф. факультетской терапии Москва, Россия
Mary E. Pyko
Federal Research Centre of Nutrition and Biotechnologyаспирант Москва, Россия
Andrei A. Pyko
Pavlov Ryazan State Medical University; Medical unit of the Ministry of Internal Affairs of Russia in the Ryazan Regionканд. мед. наук, проф. каф. факультетской терапии Рязань, Россия
References
- Kandaswamy E, Zuo L. Recent advances in treatment of coronary artery disease: role of science and technology. Int J Mol Sci 2018; 19 (2): 424.
- Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics 2012 update: a report from the American Heart Association. Circulation 2012; 3; 125 (1): 2-220.
- Шальнова С.А., Деев А.Д. Ишемическая болезнь сердца в России: распространенность и лечение (по данным клинико-эпидемиологических исследований). Т ерапевтический архив. 2011; 83 (1): 7-12.
- Балева Е.С. Оценка качества жизни в ракурсе оптимизации медико-социальной реабилитации больных ишемической болезнью. Автореф. дис.. канд. мед.наук. Волгоград, 2011.
- Nabel EG, Braunwald E. A tale of ooronary artery disease and myocardial infarction. N Engl J Med 2012; 366 (1): 54-63.
- Tomiyama H, Matsumoto C, Shiina et al. Brachial-ankle PWV: current status and future directions as a useful marker in the management of cardiovascular disease and/or cardiovascular risk factors. J Atheroscler Thromb 2016; 23 (2): 128-46.
- Морозова Т.Е., Вартанова О.А. Статины в лечении и профилактике прогрессирования атеросклероза у больных с ишемической болезнью сердца. Кардиосоматика. 2013; 1: 28-35.
- Lee SE, Chang HJ, Sung JM et al. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. JACC: Cardiovasc Imaging 2018; 11 (10): 1475-84.
- Бойцов С.А., Погосова Н.В., Бубнова М.Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Кардиоваскулярная профилактика. 2018; 6: 7-122.
- Гусев А. А. Сравнительное изучение биологических свойств сапонинов. Ветеринария. 1980; 1: 26.
- Turgeon RD, Pearson GJ. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. Am J Health Syst Pharm 2018; 75 (11): 747-54.
- Saborowski M, Dolle M, Manns MP et al. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort. Cardiol J 2018; 25 (1): 32-41.
- Шулутко И.Б., Тугбаева Л.Я., Нестеров В.А. Терапевтическая эффективность сапонинов диоскореи при лечении больных атеросклерозом. В кн.: Лекарственные средства из растений. Под ред. А.Д.Туровой. М., 1962; с. 143.
- Милимовка М.Е., Коновалов М.Н, Рыбников М.И., Димат М.И. Опыт лечения больных атеросклерозом полиспонином. Врач. дело. 1963; 1.
Supplementary files
